VERAXA Biotech AG (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the company’s proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform. This represents an early but significant step in advancing the program toward clinical development.
The BiTAC-TCE platform is designed to selectively engage T cells against cancer cells that express two specific targets, thereby reducing off-target effects common with traditional T-cell engagers. Preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 demonstrated that the lead candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies showed a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
VERAXA is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by quality-by-design principles, the company is advancing its proprietary BiTAC formats into clinical development. The BiTAC platform was developed from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL).
For more information, visit the company’s newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/jpXam.
